Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Опыт применения ингибиторов фосфодиэстеразы 4-го типа для лечения пациентов с псориатическим артритом, псориазом и коморбидными заболеваниями
Опыт применения ингибиторов фосфодиэстеразы 4-го типа для лечения пациентов с псориатическим артритом, псориазом и коморбидными заболеваниями
Гайдукова И.З., Трофимов Е.А., Пыхалова Н.Е. и др. Опыт применения ингибиторов фосфодиэстеразы 4-го типа для лечения пациентов с псориатическим артритом, псориазом и коморбидными заболеваниями. Дерматология (Прил. к журн. Consilium Medicum). 2018; 3: 9–14. DOI: 10.26442/2414-3537_2018.3.9-14
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Псориатический артрит (ПсА) – хроническое воспалительное заболевание суставов, позвоночника и энтезисов, ассоциированное с псориазом. Недавно в качестве препарата для лечения ПсА и псориаза был зарегистрирован апремиласт, ингибитор фосфодиэстеразы 4-го типа (ИФДЭ-4). Представляется перспективным применение ИФДЭ-4 для лечения пациентов с ПсА, псориазом и коморбидными состояниями.
Цель исследования – на основании собственного клинического опыта оценить эффективность и безопасность применения апремиласта для лечения больных ПсА и псориазом с коморбидными состояниями.
Материалы и методы. Выполнен ретроспективный анализ состояния 12 пациентов с активным ПсА и псориазом, получавших терапию апремиластом. Терапию апремиластом проводили врачи реальной клинической практики в соответствии с инструкцией по применению препарата. Коллекционировали исходные и полученные на фоне лечения апремиластом клинические и лабораторные показатели, отражающие активность ПсА и псориаза, а также данные о коморбидности и нежелательных явлениях.
Результаты. У 9 из 12 пациентов с активным ПсА и псориазом (средний возраст – 46±15,56 года) на фоне терапии наблюдались уменьшение выраженности кожного и суставного синдрома, разрешение внескелетных проявлений (увеит) и снижение лабораторной активности. Отменили лечение из-за отсутствия первичного ответа на терапию у 2 пациентов, из-за развития нежелательных явлений – у 1. Ухудшения коморбидной патологии, выявленной исходно у всех пациентов, не зафиксировано. Ни в одном случае не отмечено увеличения массы тела и/или дислипидемии. У 3 пациентов уменьшился индекс массы тела, у 2 стабилизировалось течение сахарного диабета, другие коморбидные состояния (хроническая обструктивная болезнь легких, ишемическая болезнь сердца, язвенная болезнь желудка и др.) не претерпели изменений на фоне лечения.
Выводы. Продемонстрирована возможность успешного применения ИФДЭ-4 для лечения пациентов с псориазом, ПсА, в том числе при наличии коморбидных состояний.
The aim of the study was to assess, based on our own clinical experience efficacy and safety of aprelimilast for the treatment of patients with PsA and psoriasis with comorbid conditions.
Materials and methods. A retrospective analysis of the condition of 12 patients with active PsA and psoriasis, who received therapy with apremilast. Aprimilast based therapy is conducted by doctors of real clinical practice in accordance with the instruction on application of the drug. Collected baseline data as well as that received on the background of treatment aprimilast clinical and laboratory indicators reflecting the activity of PsA and psoriasis, as well as data on comorbidity and undesirable phenomena.
Results. In 9 of 12 patients with active PsA and psoriasis (mean age – 46±15.56 years) on the background of therapy there was a decrease in the severity of cutaneous and articular syndrome, resolution of non-skeletal manifestations (uveitis) and reduction laboratory activity. The treatment was canceled due to a lack of primary response to therapy in 2 patients, due to the development of adverse events – in 1 deterioration The comorbid pathology revealed initially in all patients was not recorded. Neither In one case, there was no increase in body weight and / or dyslipidemia. In 3 patients the body mass index decreased, in 2 the course of diabetes mellitus stabilized, others Comorbid conditions (chronic obstructive pulmonary disease, ischemic heart disease, peptic ulcer disease, etc.) did not undergo changes in the background.
Conclusions. The possibility of the successful use of IPDE-4 for treatment of patients with psoriasis, PsA, including in the presence of comorbid conditions.
Цель исследования – на основании собственного клинического опыта оценить эффективность и безопасность применения апремиласта для лечения больных ПсА и псориазом с коморбидными состояниями.
Материалы и методы. Выполнен ретроспективный анализ состояния 12 пациентов с активным ПсА и псориазом, получавших терапию апремиластом. Терапию апремиластом проводили врачи реальной клинической практики в соответствии с инструкцией по применению препарата. Коллекционировали исходные и полученные на фоне лечения апремиластом клинические и лабораторные показатели, отражающие активность ПсА и псориаза, а также данные о коморбидности и нежелательных явлениях.
Результаты. У 9 из 12 пациентов с активным ПсА и псориазом (средний возраст – 46±15,56 года) на фоне терапии наблюдались уменьшение выраженности кожного и суставного синдрома, разрешение внескелетных проявлений (увеит) и снижение лабораторной активности. Отменили лечение из-за отсутствия первичного ответа на терапию у 2 пациентов, из-за развития нежелательных явлений – у 1. Ухудшения коморбидной патологии, выявленной исходно у всех пациентов, не зафиксировано. Ни в одном случае не отмечено увеличения массы тела и/или дислипидемии. У 3 пациентов уменьшился индекс массы тела, у 2 стабилизировалось течение сахарного диабета, другие коморбидные состояния (хроническая обструктивная болезнь легких, ишемическая болезнь сердца, язвенная болезнь желудка и др.) не претерпели изменений на фоне лечения.
Выводы. Продемонстрирована возможность успешного применения ИФДЭ-4 для лечения пациентов с псориазом, ПсА, в том числе при наличии коморбидных состояний.
________________________________________________
The aim of the study was to assess, based on our own clinical experience efficacy and safety of aprelimilast for the treatment of patients with PsA and psoriasis with comorbid conditions.
Materials and methods. A retrospective analysis of the condition of 12 patients with active PsA and psoriasis, who received therapy with apremilast. Aprimilast based therapy is conducted by doctors of real clinical practice in accordance with the instruction on application of the drug. Collected baseline data as well as that received on the background of treatment aprimilast clinical and laboratory indicators reflecting the activity of PsA and psoriasis, as well as data on comorbidity and undesirable phenomena.
Results. In 9 of 12 patients with active PsA and psoriasis (mean age – 46±15.56 years) on the background of therapy there was a decrease in the severity of cutaneous and articular syndrome, resolution of non-skeletal manifestations (uveitis) and reduction laboratory activity. The treatment was canceled due to a lack of primary response to therapy in 2 patients, due to the development of adverse events – in 1 deterioration The comorbid pathology revealed initially in all patients was not recorded. Neither In one case, there was no increase in body weight and / or dyslipidemia. In 3 patients the body mass index decreased, in 2 the course of diabetes mellitus stabilized, others Comorbid conditions (chronic obstructive pulmonary disease, ischemic heart disease, peptic ulcer disease, etc.) did not undergo changes in the background.
Conclusions. The possibility of the successful use of IPDE-4 for treatment of patients with psoriasis, PsA, including in the presence of comorbid conditions.
Полный текст
Список литературы
1. Мазуров В.И. Болезни суставов. Руководство для врачей. СПб.: СпецЛит, 2008. / Mazurov V.I. Bolezni sustavov. Rukovodstvo dlia vrachei. SPb.: SpetsLit, 2008. [in Russian]
2. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г. и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015; 53 (6): 657–60. DOI: http://dx.doi.org/10.14412/1995-4484-2015-657-660 / Erdes Sh.F., Badokin V.V., Bochkova A.G. i dr. O terminologii spondiloartritov. Nauchno-prakticheskaia revmatologiia. 2015; 53 (6): 657–60. DOI: http://dx.doi.org/10.14412/1995-4484-2015-657-660 [in Russian]
3. Федеральные клинические рекомендации по ведению больных псориазом. http://mzdrav.rk.gov.ru/file/Psoriaz_05052014_Klinicheskie_rekomendacii.pdf / Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriazom. http://mzdrav.rk.gov.ru/file/Psoriaz_05052014_Klinicheskie_rekomendacii.pdf [in Russian]
4. Федеральные клинические рекомендации по ведению больных псориатическим артритом. http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf / Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriaticheskim artritom. http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf [in Russian]
5. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68 (5): 1060–71. DOI: 10.1002/art.39573
6. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75 (3): 499–510. DOI: 10.1136/annrheumdis-2015-208337
7. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133 (2): 377–85. DOI: 10.1038/jid.2012.339
8. Гайдукова И.З., Ребров А.П. Риск появления ишемической болезни сердца у больных анкилозирующим спондилитом (болезнью Бехтерева) и псориатическим артритом по результатам десятилетнего проспективного наблюдения (исследование Прогресс). Клиницист. 2016; 10 (3): 26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31 / Gaidukova I.Z., Rebrov A.P. Risk poiavleniia ishemicheskoi bolezni serdtsa u bol'nykh ankiloziruiushchim spondilitom (bolezn'iu Bekhtereva) i psoriaticheskim artritom po rezul'tatam desiatiletnego prospektivnogo nabliudeniia (issledovanie Progress). Klinitsist. 2016; 10 (3): 26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31 [in Russian]
9. Ребров А.П., Никитина Н.М., Гайдукова И.З. Факторы риска развития сердечно-сосудистых заболеваний при псориатическом и ревматоидном артритах. Терапевтический архив. 2011; 83 (5): 20–4. / Rebrov A.P., Nikitina N.M., Gaidukova I.Z. Faktory riska razvitiia serdechno-sosudistykh zabolevanii pri psoriaticheskom i revmatoidnom artritakh. Therapeutic Archive. 2011; 83 (5): 20–4. [in Russian]
10. Lupoli R, Pizzicato P, Scalera A et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 2016; 18 (1): 297.
11. Russolillo A, Iervolino S, Peluso R et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52 (1): 62–7. DOI: 10.1093/rheumatology/kes242
12. Labitigan M, Bahče-Altuntas A, Kremer JM et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66 (4): 600–7. DOI: 10.1002/acr.22185
13. Yu Xue, Li Jiang, Qingqing Cheng et al. Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone Erosions. PLoS One 2012; 7 (10): e46740. DOI: 10.1371/journal.pone.0046740
14. Di Minno MN, Peluso R, Iervolino S et al., on behalf of the CaRRDs Study Group Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor a blockers. Ann Rheum Dis 2014; 73 (6): 1157–62. DOI: 10.1136/annrheumdis-2012-202812
15. Мазуров В.И., Трофимов Е.А. Ревматология. Фармакотерапия без ошибок: руководство для врачей. М.: Е-ното, 2017. / Mazurov V.I., Trofimov E.A. Revmatologiia. Farmakoterapiia bez oshibok: rukovodstvo dlia vrachei. M.: E-noto, 2017. [in Russian]
16. Wu C, Rajagopalan S. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders. Obes Rev 2016; 17 (5): 429–41. DOI: 10.1111/obr.12385
17. Dattola A, Del Duca E, Saraceno R et al. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf 2017; 16 (3): 381–5.
18. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Experim Rheumatol 2015; 33 (5; Suppl. 93): S2–S6.
19. Clapcote SJ. Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases. Adv Neurobiol 2017; 17: 103–31. DOI: 10.1007/978-3-319-58811-7_5
20. Jensterle M, Salamun V, Kocjan T et al. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 2015; 8: 32. DOI: 10.1186/s13048-015-0161-3
21. Jensterle M, Kocjan T, Janez A. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99 (8): E1476–81. DOI: 10.1210/jc.2014-1430
22. Avila DV, Barker DF, Zhang J et al. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. J Pathol 2016; 240 (1): 96–107. DOI: 10.1002/path.4760
23. Papadavid E, Kokkalis G, Polyderas G et al. Rapid clearance of erythrodermic psoriasis with apremilast. J Dermatol Case Rep 2017; 11 (2): 29–31. DOI: 10.3315/jdcr.2017.1246
24. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73 (1): 37–49. DOI: 10.1016/j.jaad.2015.03.049
25. Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173 (6): 1387–99. DOI: 10.1111/bjd.14164
26. Crowley J, Thaçi D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77 (2): 310–7.e1. DOI: 10.1016/j.jaad.2017.01.052
27. Bissonnette R, Pariser DM, Wasel NR et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016; 75 (1): 99–105. DOI: 10.1016/j.jaad.2016.02.1164
2. Erdes Sh.F., Badokin V.V., Bochkova A.G. i dr. O terminologii spondiloartritov. Nauchno-prakticheskaia revmatologiia. 2015; 53 (6): 657–60. DOI: http://dx.doi.org/10.14412/1995-4484-2015-657-660 [in Russian]
3. Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriazom. http://mzdrav.rk.gov.ru/file/Psoriaz_05052014_Klinicheskie_rekomendacii.pdf [in Russian]
4. Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriaticheskim artritom. http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf [in Russian]
5. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68 (5): 1060–71. DOI: 10.1002/art.39573
6. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75 (3): 499–510. DOI: 10.1136/annrheumdis-2015-208337
7. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133 (2): 377–85. DOI: 10.1038/jid.2012.339
8. Gaidukova I.Z., Rebrov A.P. Risk poiavleniia ishemicheskoi bolezni serdtsa u bol'nykh ankiloziruiushchim spondilitom (bolezn'iu Bekhtereva) i psoriaticheskim artritom po rezul'tatam desiatiletnego prospektivnogo nabliudeniia (issledovanie Progress). Klinitsist. 2016; 10 (3): 26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31 [in Russian]
9.
Rebrov A.P., Nikitina N.M., Gaidukova I.Z. Faktory riska razvitiia serdechno-sosudistykh zabolevanii pri psoriaticheskom i revmatoidnom artritakh. Therapeutic Archive. 2011; 83 (5): 20–4. [in Russian]
10. Lupoli R, Pizzicato P, Scalera A et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 2016; 18 (1): 297.
11. Russolillo A, Iervolino S, Peluso R et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52 (1): 62–7. DOI: 10.1093/rheumatology/kes242
12. Labitigan M, Bahče-Altuntas A, Kremer JM et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66 (4): 600–7. DOI: 10.1002/acr.22185
13. Yu Xue, Li Jiang, Qingqing Cheng et al. Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone Erosions. PLoS One 2012; 7 (10): e46740. DOI: 10.1371/journal.pone.0046740
14. Di Minno MN, Peluso R, Iervolino S et al., on behalf of the CaRRDs Study Group Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor a blockers. Ann Rheum Dis 2014; 73 (6): 1157–62. DOI: 10.1136/annrheumdis-2012-202812
15. Мазуров В.И., Трофимов Е.А. Ревматология. Фармакотерапия без ошибок: руководство для врачей. М.: Е-ното, 2017. / Mazurov V.I., Trofimov E.A. Revmatologiia. Farmakoterapiia bez oshibok: rukovodstvo dlia vrachei. M.: E-noto, 2017. [in Russian]
16. Wu C, Rajagopalan S. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders. Obes Rev 2016; 17 (5): 429–41. DOI: 10.1111/obr.12385
17. Dattola A, Del Duca E, Saraceno R et al. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf 2017; 16 (3): 381–5.
18. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Experim Rheumatol 2015; 33 (5; Suppl. 93): S2–S6.
19. Clapcote SJ. Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases. Adv Neurobiol 2017; 17: 103–31. DOI: 10.1007/978-3-319-58811-7_5
20. Jensterle M, Salamun V, Kocjan T et al. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 2015; 8: 32. DOI: 10.1186/s13048-015-0161-3
21. Jensterle M, Kocjan T, Janez A. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99 (8): E1476–81. DOI: 10.1210/jc.2014-1430
22. Avila DV, Barker DF, Zhang J et al. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. J Pathol 2016; 240 (1): 96–107. DOI: 10.1002/path.4760
23. Papadavid E, Kokkalis G, Polyderas G et al. Rapid clearance of erythrodermic psoriasis with apremilast. J Dermatol Case Rep 2017; 11 (2): 29–31. DOI: 10.3315/jdcr.2017.1246
24. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73 (1): 37–49. DOI: 10.1016/j.jaad.2015.03.049
25. Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173 (6): 1387–99. DOI: 10.1111/bjd.14164
26. Crowley J, Thaçi D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77 (2): 310–7.e1. DOI: 10.1016/j.jaad.2017.01.052
27. Bissonnette R, Pariser DM, Wasel NR et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016; 75 (1): 99–105. DOI: 10.1016/j.jaad.2016.02.1164
2. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г. и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015; 53 (6): 657–60. DOI: http://dx.doi.org/10.14412/1995-4484-2015-657-660 / Erdes Sh.F., Badokin V.V., Bochkova A.G. i dr. O terminologii spondiloartritov. Nauchno-prakticheskaia revmatologiia. 2015; 53 (6): 657–60. DOI: http://dx.doi.org/10.14412/1995-4484-2015-657-660 [in Russian]
3. Федеральные клинические рекомендации по ведению больных псориазом. http://mzdrav.rk.gov.ru/file/Psoriaz_05052014_Klinicheskie_rekomendacii.pdf / Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriazom. http://mzdrav.rk.gov.ru/file/Psoriaz_05052014_Klinicheskie_rekomendacii.pdf [in Russian]
4. Федеральные клинические рекомендации по ведению больных псориатическим артритом. http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf / Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriaticheskim artritom. http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf [in Russian]
5. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68 (5): 1060–71. DOI: 10.1002/art.39573
6. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75 (3): 499–510. DOI: 10.1136/annrheumdis-2015-208337
7. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133 (2): 377–85. DOI: 10.1038/jid.2012.339
8. Гайдукова И.З., Ребров А.П. Риск появления ишемической болезни сердца у больных анкилозирующим спондилитом (болезнью Бехтерева) и псориатическим артритом по результатам десятилетнего проспективного наблюдения (исследование Прогресс). Клиницист. 2016; 10 (3): 26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31 / Gaidukova I.Z., Rebrov A.P. Risk poiavleniia ishemicheskoi bolezni serdtsa u bol'nykh ankiloziruiushchim spondilitom (bolezn'iu Bekhtereva) i psoriaticheskim artritom po rezul'tatam desiatiletnego prospektivnogo nabliudeniia (issledovanie Progress). Klinitsist. 2016; 10 (3): 26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31 [in Russian]
9. Ребров А.П., Никитина Н.М., Гайдукова И.З. Факторы риска развития сердечно-сосудистых заболеваний при псориатическом и ревматоидном артритах. Терапевтический архив. 2011; 83 (5): 20–4. / Rebrov A.P., Nikitina N.M., Gaidukova I.Z. Faktory riska razvitiia serdechno-sosudistykh zabolevanii pri psoriaticheskom i revmatoidnom artritakh. Therapeutic Archive. 2011; 83 (5): 20–4. [in Russian]
10. Lupoli R, Pizzicato P, Scalera A et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 2016; 18 (1): 297.
11. Russolillo A, Iervolino S, Peluso R et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52 (1): 62–7. DOI: 10.1093/rheumatology/kes242
12. Labitigan M, Bahče-Altuntas A, Kremer JM et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66 (4): 600–7. DOI: 10.1002/acr.22185
13. Yu Xue, Li Jiang, Qingqing Cheng et al. Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone Erosions. PLoS One 2012; 7 (10): e46740. DOI: 10.1371/journal.pone.0046740
14. Di Minno MN, Peluso R, Iervolino S et al., on behalf of the CaRRDs Study Group Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor a blockers. Ann Rheum Dis 2014; 73 (6): 1157–62. DOI: 10.1136/annrheumdis-2012-202812
15. Мазуров В.И., Трофимов Е.А. Ревматология. Фармакотерапия без ошибок: руководство для врачей. М.: Е-ното, 2017. / Mazurov V.I., Trofimov E.A. Revmatologiia. Farmakoterapiia bez oshibok: rukovodstvo dlia vrachei. M.: E-noto, 2017. [in Russian]
16. Wu C, Rajagopalan S. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders. Obes Rev 2016; 17 (5): 429–41. DOI: 10.1111/obr.12385
17. Dattola A, Del Duca E, Saraceno R et al. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf 2017; 16 (3): 381–5.
18. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Experim Rheumatol 2015; 33 (5; Suppl. 93): S2–S6.
19. Clapcote SJ. Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases. Adv Neurobiol 2017; 17: 103–31. DOI: 10.1007/978-3-319-58811-7_5
20. Jensterle M, Salamun V, Kocjan T et al. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 2015; 8: 32. DOI: 10.1186/s13048-015-0161-3
21. Jensterle M, Kocjan T, Janez A. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99 (8): E1476–81. DOI: 10.1210/jc.2014-1430
22. Avila DV, Barker DF, Zhang J et al. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. J Pathol 2016; 240 (1): 96–107. DOI: 10.1002/path.4760
23. Papadavid E, Kokkalis G, Polyderas G et al. Rapid clearance of erythrodermic psoriasis with apremilast. J Dermatol Case Rep 2017; 11 (2): 29–31. DOI: 10.3315/jdcr.2017.1246
24. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73 (1): 37–49. DOI: 10.1016/j.jaad.2015.03.049
25. Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173 (6): 1387–99. DOI: 10.1111/bjd.14164
26. Crowley J, Thaçi D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77 (2): 310–7.e1. DOI: 10.1016/j.jaad.2017.01.052
27. Bissonnette R, Pariser DM, Wasel NR et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016; 75 (1): 99–105. DOI: 10.1016/j.jaad.2016.02.1164
________________________________________________
2. Erdes Sh.F., Badokin V.V., Bochkova A.G. i dr. O terminologii spondiloartritov. Nauchno-prakticheskaia revmatologiia. 2015; 53 (6): 657–60. DOI: http://dx.doi.org/10.14412/1995-4484-2015-657-660 [in Russian]
3. Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriazom. http://mzdrav.rk.gov.ru/file/Psoriaz_05052014_Klinicheskie_rekomendacii.pdf [in Russian]
4. Federal'nye klinicheskie rekomendatsii po vedeniiu bol'nykh psoriaticheskim artritom. http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf [in Russian]
5. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68 (5): 1060–71. DOI: 10.1002/art.39573
6. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75 (3): 499–510. DOI: 10.1136/annrheumdis-2015-208337
7. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133 (2): 377–85. DOI: 10.1038/jid.2012.339
8. Gaidukova I.Z., Rebrov A.P. Risk poiavleniia ishemicheskoi bolezni serdtsa u bol'nykh ankiloziruiushchim spondilitom (bolezn'iu Bekhtereva) i psoriaticheskim artritom po rezul'tatam desiatiletnego prospektivnogo nabliudeniia (issledovanie Progress). Klinitsist. 2016; 10 (3): 26–31. DOI: 10.17650/1818-8338-2016-10-3-26-31 [in Russian]
9.
Rebrov A.P., Nikitina N.M., Gaidukova I.Z. Faktory riska razvitiia serdechno-sosudistykh zabolevanii pri psoriaticheskom i revmatoidnom artritakh. Therapeutic Archive. 2011; 83 (5): 20–4. [in Russian]
10. Lupoli R, Pizzicato P, Scalera A et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 2016; 18 (1): 297.
11. Russolillo A, Iervolino S, Peluso R et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52 (1): 62–7. DOI: 10.1093/rheumatology/kes242
12. Labitigan M, Bahče-Altuntas A, Kremer JM et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66 (4): 600–7. DOI: 10.1002/acr.22185
13. Yu Xue, Li Jiang, Qingqing Cheng et al. Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone Erosions. PLoS One 2012; 7 (10): e46740. DOI: 10.1371/journal.pone.0046740
14. Di Minno MN, Peluso R, Iervolino S et al., on behalf of the CaRRDs Study Group Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor a blockers. Ann Rheum Dis 2014; 73 (6): 1157–62. DOI: 10.1136/annrheumdis-2012-202812
15. Мазуров В.И., Трофимов Е.А. Ревматология. Фармакотерапия без ошибок: руководство для врачей. М.: Е-ното, 2017. / Mazurov V.I., Trofimov E.A. Revmatologiia. Farmakoterapiia bez oshibok: rukovodstvo dlia vrachei. M.: E-noto, 2017. [in Russian]
16. Wu C, Rajagopalan S. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders. Obes Rev 2016; 17 (5): 429–41. DOI: 10.1111/obr.12385
17. Dattola A, Del Duca E, Saraceno R et al. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf 2017; 16 (3): 381–5.
18. Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine. Clin Experim Rheumatol 2015; 33 (5; Suppl. 93): S2–S6.
19. Clapcote SJ. Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases. Adv Neurobiol 2017; 17: 103–31. DOI: 10.1007/978-3-319-58811-7_5
20. Jensterle M, Salamun V, Kocjan T et al. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res 2015; 8: 32. DOI: 10.1186/s13048-015-0161-3
21. Jensterle M, Kocjan T, Janez A. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99 (8): E1476–81. DOI: 10.1210/jc.2014-1430
22. Avila DV, Barker DF, Zhang J et al. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol-induced steatosis. J Pathol 2016; 240 (1): 96–107. DOI: 10.1002/path.4760
23. Papadavid E, Kokkalis G, Polyderas G et al. Rapid clearance of erythrodermic psoriasis with apremilast. J Dermatol Case Rep 2017; 11 (2): 29–31. DOI: 10.3315/jdcr.2017.1246
24. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73 (1): 37–49. DOI: 10.1016/j.jaad.2015.03.049
25. Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173 (6): 1387–99. DOI: 10.1111/bjd.14164
26. Crowley J, Thaçi D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77 (2): 310–7.e1. DOI: 10.1016/j.jaad.2017.01.052
27. Bissonnette R, Pariser DM, Wasel NR et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016; 75 (1): 99–105. DOI: 10.1016/j.jaad.2016.02.1164
Авторы
И.З.Гайдукова*1, Е.А.Трофимов1, Н.Е.Пыхалова2, М.А.Малахова2, О.В.Инамова3, В.И.Мазуров1
1. ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
2. МБУЗ «Красноармейская центральная районная больница». 353800, Россия, Краснодарский край, станица Полтавская, ул. Просвещения, д. 59, к. 3;
3. СПб ГБУЗ «Клиническая ревматологическая больница №25». 190068, Россия, Санкт-Петербург, ул. Большая Подьяческая, д. 30
*ubp1976@list.ru
1. I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
2. Krasnoarmeysk Сentral Dictrict Hospital.
353800, Russian Federation, Krasnodar Krai, stanitsa Poltavskaia, ul. Prosveshcheniia, d. 59, k. 3;
3. Clinical Rheumatological Hospital №25. 190068, Russian Federation, Saint Petersburg, ul. Bol'shaia Pod'iacheskaia, d. 30
*ubp1976@list.ru
1. ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
2. МБУЗ «Красноармейская центральная районная больница». 353800, Россия, Краснодарский край, станица Полтавская, ул. Просвещения, д. 59, к. 3;
3. СПб ГБУЗ «Клиническая ревматологическая больница №25». 190068, Россия, Санкт-Петербург, ул. Большая Подьяческая, д. 30
*ubp1976@list.ru
________________________________________________
1. I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
2. Krasnoarmeysk Сentral Dictrict Hospital.
353800, Russian Federation, Krasnodar Krai, stanitsa Poltavskaia, ul. Prosveshcheniia, d. 59, k. 3;
3. Clinical Rheumatological Hospital №25. 190068, Russian Federation, Saint Petersburg, ul. Bol'shaia Pod'iacheskaia, d. 30
*ubp1976@list.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.